ANIP Insider Transactions
Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
---|---|---|---|---|---|---|---|---|
2024-03-23 | CAREY STEPHEN P. | officer: SVP & CFO | 171,502 | F-InKind | D | 6,210 | 69.58 | 432,092.00 |
2024-03-23 | Marken James G. | officer: SVP OPS & PROD DEV | 118,805 | F-InKind | D | 3,653 | 69.58 | 254,176.00 |
2024-03-23 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | 394,174 | F-InKind | D | 17,455 | 69.58 | 1,214,519.00 |
2024-03-13 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | 59,981 | S-Sale | D | 250 | 66.54 | 16,635.00 |
2024-03-11 | Gassert Chad | officer: SVP - CORP. DEV. & STRATEGY | 273,226 | S-Sale | D | 20,000 | 65.81 | 1,316,200.00 |
2024-03-08 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 832,620 | S-Sale | D | 10,000 | 67.17 | 671,700.00 |
2024-03-07 | CAREY STEPHEN P. | officer: SVP & CFO | 185,499 | F-InKind | D | 4,216 | 66.71 | 281,249.00 |
2024-03-11 | CAREY STEPHEN P. | officer: SVP & CFO | 177,712 | S-Sale | D | 7,787 | 65.55 | 510,438.00 |
2024-03-06 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | 444,981 | S-Sale | D | 28,965 | 65.52 | 1,897,787.00 |
2024-03-07 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | 427,921 | F-InKind | D | 17,060 | 66.71 | 1,138,073.00 |
2024-03-08 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | 411,629 | S-Sale | D | 16,292 | 67.13 | 1,093,682.00 |
2024-03-07 | Marken James G. | officer: SVP OPS & PROD DEV | 124,492 | S-Sale | D | 24,338 | 66.37 | 1,615,313.00 |
2024-03-07 | Marken James G. | officer: SVP OPS & PROD DEV | 122,458 | F-InKind | D | 2,034 | 66.71 | 135,688.00 |
2024-03-07 | Gutwerg Ori | officer: SVP, GENERICS | 80,212 | F-InKind | D | 2,494 | 66.71 | 166,375.00 |
2024-03-07 | Mutz Christopher | officer: HEAD OF RARE DISEASE | 85,277 | F-InKind | D | 2,110 | 66.71 | 140,758.00 |
2024-03-05 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 872,527 | S-Sale | D | 10,093 | 65.35 | 659,578.00 |
2024-03-06 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 857,705 | S-Sale | D | 14,822 | 65.47 | 970,396.00 |
2024-03-07 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 842,620 | S-Sale | D | 15,085 | 66.35 | 1,000,890.00 |
2024-03-05 | Mutz Christopher | officer: HEAD OF RARE DISEASE | 87,387 | S-Sale | D | 5,000 | 66.00 | 330,000.00 |
2024-03-04 | Pera Antonio R | director | 26,627 | S-Sale | D | 7,000 | 65.20 | 456,400.00 |
2024-02-29 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 68,652 | F-InKind | D | 1,122 | 67.67 | 75,926.00 |
2024-02-29 | Mutz Christopher | officer: HEAD OF RARE DISEASE | 92,387 | F-InKind | D | 1,275 | 67.67 | 86,279.00 |
2024-02-29 | Marken James G. | officer: SVP OPS & PROD DEV | 148,830 | F-InKind | D | 1,058 | 67.67 | 71,595.00 |
2024-02-29 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | 473,946 | F-InKind | D | 10,014 | 67.67 | 677,647.00 |
2024-02-29 | Gutwerg Ori | officer: SVP, GENERICS | 82,706 | F-InKind | D | 1,570 | 67.67 | 106,242.00 |
2024-02-29 | Gassert Chad | officer: SVP - CORP. DEV. & STRATEGY | 49,679 | F-InKind | D | 1,635 | 67.67 | 110,640.00 |
2024-02-29 | Davis Krista | officer: SVP, CHIEF HR OFFICER | 51,545 | F-InKind | D | 1,173 | 67.67 | 79,377.00 |
2024-02-29 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | 60,231 | F-InKind | D | 1,173 | 67.67 | 79,377.00 |
2024-02-29 | CAREY STEPHEN P. | officer: SVP & CFO | 189,715 | F-InKind | D | 1,914 | 67.67 | 129,520.00 |
2024-02-15 | Gutwerg Ori | officer: SVP, GENERICS | 84,276 | F-InKind | D | 1,244 | 57.55 | 71,592.00 |
2024-02-15 | Mutz Christopher | officer: HEAD OF RARE DISEASE | 93,662 | F-InKind | D | 1,261 | 57.55 | 72,571.00 |
2024-02-14 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | 483,960 | A-Award | A | 53,686 | 0.00 | 0.00 |
2024-02-14 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | 430,274 | A-Award | A | 80,530 | 0.00 | 0.00 |
2024-02-14 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 69,774 | A-Award | A | 8,946 | 0.00 | 0.00 |
2024-02-14 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 60,828 | A-Award | A | 13,421 | 0.00 | 0.00 |
2024-02-14 | Mutz Christopher | officer: HEAD OF RARE DISEASE | 94,923 | A-Award | A | 12,526 | 0.00 | 0.00 |
2024-02-14 | Mutz Christopher | officer: HEAD OF RARE DISEASE | 82,397 | A-Award | A | 18,790 | 0.00 | 0.00 |
2024-02-14 | Marken James G. | officer: SVP OPS & PROD DEV | 149,888 | A-Award | A | 6,710 | 0.00 | 0.00 |
2024-02-14 | Marken James G. | officer: SVP OPS & PROD DEV | 143,178 | A-Award | A | 10,066 | 0.00 | 0.00 |
2024-02-14 | Gutwerg Ori | officer: SVP, GENERICS | 85,520 | A-Award | A | 9,842 | 0.00 | 0.00 |
2024-02-14 | Gutwerg Ori | officer: SVP, GENERICS | 75,678 | A-Award | A | 14,763 | 0.00 | 0.00 |
2024-02-14 | Gassert Chad | officer: SVP - CORP. DEV. & STRATEGY | 51,314 | A-Award | A | 8,946 | 0.00 | 0.00 |
2024-02-14 | Gassert Chad | officer: SVP - CORP. DEV. & STRATEGY | 42,368 | A-Award | A | 13,421 | 0.00 | 0.00 |
2024-02-14 | Davis Krista | officer: SVP, CHIEF HR OFFICER | 52,718 | A-Award | A | 8,052 | 0.00 | 0.00 |
2024-02-14 | Davis Krista | officer: SVP, CHIEF HR OFFICER | 44,666 | A-Award | A | 12,079 | 0.00 | 0.00 |
2024-02-14 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | 61,404 | A-Award | A | 9,842 | 0.00 | 0.00 |
2024-02-14 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | 51,562 | A-Award | A | 14,763 | 0.00 | 0.00 |
2024-02-14 | CAREY STEPHEN P. | officer: SVP & CFO | 191,629 | A-Award | A | 14,316 | 0.00 | 0.00 |
2024-02-14 | CAREY STEPHEN P. | officer: SVP & CFO | 177,313 | A-Award | A | 21,474 | 0.00 | 0.00 |
2024-02-13 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | 36,799 | S-Sale | D | 250 | 56.04 | 14,010.00 |
2024-01-19 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 903,312 | S-Sale | D | 4,524 | 55.57 | 251,399.00 |
2024-01-22 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 897,620 | S-Sale | D | 5,692 | 55.95 | 318,467.00 |
2024-01-23 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 882,620 | S-Sale | D | 15,000 | 56.44 | 846,600.00 |
2024-01-16 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 927,620 | S-Sale | D | 5,000 | 55.63 | 278,150.00 |
2024-01-17 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 917,620 | S-Sale | D | 10,000 | 55.11 | 551,100.00 |
2024-01-18 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 907,836 | S-Sale | D | 9,784 | 55.30 | 541,055.00 |
2024-01-12 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | 37,049 | S-Sale | D | 250 | 56.43 | 14,108.00 |
2023-12-15 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 970,646 | S-Sale | D | 11,974 | 52.44 | 627,917.00 |
2023-12-18 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 957,620 | S-Sale | D | 13,026 | 52.44 | 683,083.00 |
2023-12-19 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 932,620 | S-Sale | D | 25,000 | 52.65 | 1,316,250.00 |
2023-12-11 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | 37,299 | S-Sale | D | 250 | 49.21 | 12,302.00 |
2023-11-17 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 982,620 | S-Sale | D | 13,000 | 51.00 | 663,000.00 |
2023-11-14 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,009,715 | S-Sale | D | 22,905 | 53.17 | 1,217,859.00 |
2023-11-15 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,002,068 | S-Sale | D | 7,647 | 53.64 | 410,185.00 |
2023-11-16 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 995,620 | S-Sale | D | 6,448 | 51.66 | 333,104.00 |
2023-11-15 | Davis Krista | officer: SVP, CHIEF HR OFFICER | 32,587 | S-Sale | D | 2,622 | 53.81 | 141,090.00 |
2023-11-14 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,010,525 | S-Sale | D | 22,095 | 53.17 | 1,174,791.00 |
2023-11-15 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,002,878 | S-Sale | D | 7,647 | 53.64 | 410,185.00 |
2023-11-16 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 996,430 | S-Sale | D | 6,448 | 51.66 | 333,104.00 |
2023-11-10 | Mutz Christopher | officer: HEAD OF RARE DISEASE | 63,607 | S-Sale | D | 3,000 | 52.47 | 157,410.00 |
2023-10-17 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,048,862 | S-Sale | D | 8,758 | 58.53 | 512,606.00 |
2023-10-18 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,042,620 | S-Sale | D | 6,242 | 57.78 | 360,663.00 |
2023-10-19 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,032,620 | S-Sale | D | 10,000 | 57.06 | 570,600.00 |
2023-10-13 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,070,683 | S-Sale | D | 11,937 | 57.58 | 687,332.00 |
2023-10-16 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,057,620 | S-Sale | D | 13,063 | 58.31 | 761,704.00 |
2023-10-02 | Gassert Chad | officer: SVP - CORP. DEV. & STRATEGY | 293,226 | S-Sale | D | 20,000 | 56.48 | 1,129,600.00 |
2023-09-15 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,116,378 | S-Sale | D | 16,242 | 62.81 | 1,020,160.00 |
2023-09-18 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,107,953 | S-Sale | D | 8,425 | 61.64 | 519,317.00 |
2023-09-19 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,082,620 | S-Sale | D | 25,333 | 61.23 | 1,551,140.00 |
2023-09-12 | Davis Krista | officer: SVP, CHIEF HR OFFICER | 35,209 | F-InKind | D | 1,486 | 61.91 | 91,998.00 |
2023-09-08 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | 349,744 | F-InKind | D | 3,646 | 61.94 | 225,833.00 |
2023-09-01 | Gassert Chad | officer: SVP - CORP. DEV. & STRATEGY | 313,226 | S-Sale | D | 20,000 | 64.70 | 1,294,000.00 |
2023-08-28 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,157,620 | S-Sale | D | 25,000 | 63.06 | 1,576,500.00 |
2023-08-29 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,132,620 | S-Sale | D | 25,000 | 63.37 | 1,584,250.00 |
2023-08-23 | Gutwerg Ori | officer: SVP, GENERICS | 76,476 | M-Exempt | A | 13,502 | 31.49 | 425,178.00 |
2023-08-23 | Gutwerg Ori | officer: SVP, GENERICS | 62,974 | S-Sale | D | 13,502 | 62.39 | 842,390.00 |
2023-08-23 | Gutwerg Ori | officer: SVP, GENERICS | 60,915 | S-Sale | D | 2,059 | 62.39 | 128,461.00 |
2023-08-23 | Gutwerg Ori | officer: SVP, GENERICS | 13,504 | M-Exempt | D | 13,502 | 31.49 | 425,178.00 |
2023-08-23 | Marken James G. | officer: SVP OPS & PROD DEV | 137,044 | M-Exempt | A | 1,667 | 33.00 | 55,011.00 |
2023-08-23 | Marken James G. | officer: SVP OPS & PROD DEV | 135,377 | M-Exempt | A | 3,750 | 40.59 | 152,212.00 |
2023-08-23 | Marken James G. | officer: SVP OPS & PROD DEV | 133,112 | S-Sale | D | 3,932 | 63.00 | 247,716.00 |
2023-08-23 | Marken James G. | officer: SVP OPS & PROD DEV | 0 | M-Exempt | D | 3,750 | 40.59 | 152,212.00 |
2023-08-23 | Marken James G. | officer: SVP OPS & PROD DEV | 0 | M-Exempt | D | 1,667 | 33.00 | 55,011.00 |
2023-08-21 | Leonard Matthew J | director | 7,583 | A-Award | A | 7,583 | 0.00 | 0.00 |
2023-08-21 | Leonard Matthew J | director: | 0 | 0 | 0.00 | 0.00 | ||
2023-08-16 | MERIDIAN VENTURE PARTNERS II LP | 10 percent owner | 1,819,259 | S-Sale | D | 200,000 | 58.50 | 11,700,000.00 |
2023-08-14 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,204,730 | S-Sale | D | 27,890 | 61.15 | 1,705,474.00 |
2023-08-15 | Shanmugam Muthusamy | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 1,182,620 | S-Sale | D | 22,110 | 61.60 | 1,361,976.00 |
2023-08-14 | CAREY STEPHEN P. | officer: SVP & CFO | 155,839 | S-Sale | D | 17,639 | 61.37 | 1,082,505.00 |
2023-08-14 | Pera Antonio R | director | 33,627 | S-Sale | D | 3,000 | 60.37 | 181,110.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.